BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191103T080000
DTEND;TZID=America/New_York:20191115T170000
DTSTAMP:20260715T030505
CREATED:20191021T132047Z
LAST-MODIFIED:20191021T132047Z
UID:6876-1572768000-1573837200@scienceinboston.com
SUMMARY:Leadership Development for Physicians in Academic Health Centers
DESCRIPTION:Overview\n\nAcademic health centers in the United States are experiencing major change as a result of the effects of health reform and financial pressures. In addition to the restructuring of the clinical enterprise\, academic centers are being challenged to sustain their academic missions and priorities in the face of resource constraints. In order to tackle these challenges\, institutions need physicians in administrative positions at all levels who can provide leadership and thoughtful managerial initiatives. \nFor over forty years Harvard has conducted intensive two-week executive development programs designed specifically for chairs\, chiefs\, and medical directors in clinical departments at major teaching hospitals. During that time\, leaders from institutions in all regions of the United States have participated in and praised these unique educational programs. \nLeadership Development for Physicians in Academic Health Centers is designed to serve a wide array of physician leaders. It convenes medical directors and chiefs of divisions from academic health centers together with an interdisciplinary faculty team for two weeks of intensive and systematic study of the critical leadership and management issues faced by physicians in administrative positions and academic health centers. \nCurriculum \nThe curriculum is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nFinancial Analysis\nOperations Management\nOrganizational Issues\nConflict Resolution and Negotiation\nLeadership\nHealth Policy\n\nA carefully integrated curriculum permits participants to examine fundamental leadership and managerial issues from the perspective of several disciplines. The overriding purpose for learning concepts\, techniques and skills in any of the management disciplines in this program is to understand their managerial use and limitations. \nTeaching Methods \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at the Harvard Business School. Most of the cases present actual problem situations familiar to physicians in administrative positions at academic health centers. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and empowers the participant to choose a course of action. \nParticipants go through a three-step study process. First\, participants study each case independently. Then they meet in small discussion groups to test their individual analysis against those of their peers. Lastly\, the entire class discusses the case\, with the professor as a catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and between participants and faculty. \nCourse Website
URL:https://scienceinboston.com/event/leadership-development-for-physicians-in-academic-health-centers/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191103T080000
DTEND;TZID=America/New_York:20191115T170000
DTSTAMP:20260715T030505
CREATED:20191021T132047Z
LAST-MODIFIED:20191021T132047Z
UID:27348-1572768000-1573837200@scienceinboston.com
SUMMARY:Leadership Development for Physicians in Academic Health Centers
DESCRIPTION:Overview\n\nAcademic health centers in the United States are experiencing major change as a result of the effects of health reform and financial pressures. In addition to the restructuring of the clinical enterprise\, academic centers are being challenged to sustain their academic missions and priorities in the face of resource constraints. In order to tackle these challenges\, institutions need physicians in administrative positions at all levels who can provide leadership and thoughtful managerial initiatives. \nFor over forty years Harvard has conducted intensive two-week executive development programs designed specifically for chairs\, chiefs\, and medical directors in clinical departments at major teaching hospitals. During that time\, leaders from institutions in all regions of the United States have participated in and praised these unique educational programs. \nLeadership Development for Physicians in Academic Health Centers is designed to serve a wide array of physician leaders. It convenes medical directors and chiefs of divisions from academic health centers together with an interdisciplinary faculty team for two weeks of intensive and systematic study of the critical leadership and management issues faced by physicians in administrative positions and academic health centers. \nCurriculum \nThe curriculum is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nFinancial Analysis\nOperations Management\nOrganizational Issues\nConflict Resolution and Negotiation\nLeadership\nHealth Policy\n\nA carefully integrated curriculum permits participants to examine fundamental leadership and managerial issues from the perspective of several disciplines. The overriding purpose for learning concepts\, techniques and skills in any of the management disciplines in this program is to understand their managerial use and limitations. \nTeaching Methods \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at the Harvard Business School. Most of the cases present actual problem situations familiar to physicians in administrative positions at academic health centers. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and empowers the participant to choose a course of action. \nParticipants go through a three-step study process. First\, participants study each case independently. Then they meet in small discussion groups to test their individual analysis against those of their peers. Lastly\, the entire class discusses the case\, with the professor as a catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and between participants and faculty. \nCourse Website
URL:https://scienceinboston.com/event/leadership-development-for-physicians-in-academic-health-centers-2/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T103000
DTEND;TZID=America/New_York:20191105T143000
DTSTAMP:20260715T030505
CREATED:20191021T134627Z
LAST-MODIFIED:20191021T134627Z
UID:6890-1572949800-1572964200@scienceinboston.com
SUMMARY:Mansfield Bio-Incubator's Second Annual Open House
DESCRIPTION:Overview\n\n  \nMansfield Bio-Incubator invites you to attend its second annual Open House on November 5\, 2019 in Mansfield\, Massachusetts. Come join in the fun and see how innovative startup companies are transforming the world with game-changing inventions in life science! \nOver the past year\,  we have added several new exciting startups while our resident companies have been growing and made progress in their research. \nWe are now gearing to expand beyond our 10\,000 sqft space. Up to 1M sqft of the R&D and manufacturing space is planned to house both earlier-stage and mature life science companies. In this way\, we are catalyzing the transformation of the entire 63-acre former glass bottling factory into a 21st century LIfe Science R&D and manufacturing campus. \nSee more information here! \nThis transformation is all due to the cutting edge science and product development going on in the proof of concept laboratories in the incubator.  We have nucleated the life science ecosystem South of Boston and the success is due to you! \nCome see for yourself that the biotechnology supercluster extends along the South of Boston innovation corridor right here to Mansfield\, Massachusetts. Join in the celebration and envision a future for yourself and your company alongside these pioneers. \nYou are invited to celebrate\, connect and launch! Collaborators\, investments and companies are all right here waiting to meet you. If you are working to find a cure for cancer\, detect disease earlier than ever before or treat diseases that have long been neglected\, you will find a home right here at the Mansfield Bio-Incubator. With fourteen (14) life science companies in place already\, the space is nearly filled to capacity\, but there may be an open spot left\, so hurry and hear from the select resident companies themselves of the benefits of being part of the emerging South of Boston innovation ecosystem. \nWe invite you to check our portfolio companies at: https://www.bioinc.org/portfolio/ \nAgenda: \n10:30 am:    Registration\, Networking and Refreshments \n11:00 am-12 noon:   Welcome (Confirmed Speakers): \n\nRuss Yukhananov\, President\, Mansfield Bio-Incubator\n\nPaul Feeney\,  Massachusetts Senator\, Representing Norfolk &Bristol\n\nRobert Coughlin\, President &CEO\, Massachusetts Biotechnology Council\n\nChristopher Gilrein\, Business Development\, Massachusetts Life Science Center\n\nMike Kennealy\, Secretary\, Executive Office of Housing and Economic Development for the Commonwealth of Massachusetts\n\n\n12:00 noon -1 pm:    Company Presentations\n\n\n1 pm-2:30 pm:    Product Demonstrations\, Continued Networking and Celebrating\, and Facility Tours\n\nPresenting companies (confirmed):\nGAMA Therapeutics is developing photodisinfection therapies and devices in combination with antimicrobial photosensitizers \nHilltop Biosciences is helping animals heal faster\, stronger using next generation allogeneic tissue-we make it easier to treat soft tissue injuries \nEightyEight Pharma is tackling the opioid epidemic by providing an innovative  Oppotoxy™ Bottle\, an opioid abuse deterrent packaging platform.
URL:https://scienceinboston.com/event/mansfield-bio-incubators-second-annual-open-house/
LOCATION:Mansfield Bio-Incubator\, 241 Francis Avenue\, Mansfield\, MA\, 02048\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T103000
DTEND;TZID=America/New_York:20191105T143000
DTSTAMP:20260715T030505
CREATED:20191021T134627Z
LAST-MODIFIED:20191021T134627Z
UID:27352-1572949800-1572964200@scienceinboston.com
SUMMARY:Mansfield Bio-Incubator's Second Annual Open House
DESCRIPTION:Overview\n\n  \nMansfield Bio-Incubator invites you to attend its second annual Open House on November 5\, 2019 in Mansfield\, Massachusetts. Come join in the fun and see how innovative startup companies are transforming the world with game-changing inventions in life science! \nOver the past year\,  we have added several new exciting startups while our resident companies have been growing and made progress in their research. \nWe are now gearing to expand beyond our 10\,000 sqft space. Up to 1M sqft of the R&D and manufacturing space is planned to house both earlier-stage and mature life science companies. In this way\, we are catalyzing the transformation of the entire 63-acre former glass bottling factory into a 21st century LIfe Science R&D and manufacturing campus. \nSee more information here! \nThis transformation is all due to the cutting edge science and product development going on in the proof of concept laboratories in the incubator.  We have nucleated the life science ecosystem South of Boston and the success is due to you! \nCome see for yourself that the biotechnology supercluster extends along the South of Boston innovation corridor right here to Mansfield\, Massachusetts. Join in the celebration and envision a future for yourself and your company alongside these pioneers. \nYou are invited to celebrate\, connect and launch! Collaborators\, investments and companies are all right here waiting to meet you. If you are working to find a cure for cancer\, detect disease earlier than ever before or treat diseases that have long been neglected\, you will find a home right here at the Mansfield Bio-Incubator. With fourteen (14) life science companies in place already\, the space is nearly filled to capacity\, but there may be an open spot left\, so hurry and hear from the select resident companies themselves of the benefits of being part of the emerging South of Boston innovation ecosystem. \nWe invite you to check our portfolio companies at: https://www.bioinc.org/portfolio/ \nAgenda: \n10:30 am:    Registration\, Networking and Refreshments \n11:00 am-12 noon:   Welcome (Confirmed Speakers): \n\nRuss Yukhananov\, President\, Mansfield Bio-Incubator\n\nPaul Feeney\,  Massachusetts Senator\, Representing Norfolk &Bristol\n\nRobert Coughlin\, President &CEO\, Massachusetts Biotechnology Council\n\nChristopher Gilrein\, Business Development\, Massachusetts Life Science Center\n\nMike Kennealy\, Secretary\, Executive Office of Housing and Economic Development for the Commonwealth of Massachusetts\n\n\n12:00 noon -1 pm:    Company Presentations\n\n\n1 pm-2:30 pm:    Product Demonstrations\, Continued Networking and Celebrating\, and Facility Tours\n\nPresenting companies (confirmed):\nGAMA Therapeutics is developing photodisinfection therapies and devices in combination with antimicrobial photosensitizers \nHilltop Biosciences is helping animals heal faster\, stronger using next generation allogeneic tissue-we make it easier to treat soft tissue injuries \nEightyEight Pharma is tackling the opioid epidemic by providing an innovative  Oppotoxy™ Bottle\, an opioid abuse deterrent packaging platform.
URL:https://scienceinboston.com/event/mansfield-bio-incubators-second-annual-open-house-2/
LOCATION:Mansfield Bio-Incubator\, 241 Francis Avenue\, Mansfield\, MA\, 02048\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T180000
DTEND;TZID=America/New_York:20191105T200000
DTSTAMP:20260715T030505
CREATED:20191021T134936Z
LAST-MODIFIED:20191021T134936Z
UID:6894-1572976800-1572984000@scienceinboston.com
SUMMARY:Alexion Research: Building a Pipeline to Service Patients with Rare Disease
DESCRIPTION:BioXchange and Alexion Pharmaceuticals Present: Sharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals\n\n\n\n\n\n\nAbout this Event\n\n\n\nThis event is one of two sessions: \nBoston\, MA – November 5th \nNew Haven\, CT – November 12th \nOverview: \nSharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals; will provide an overview of Alexion Pharmaceuticals and the overall company culture. Along with this\, she will go into a deep discussion with regards to the research the company is currently working on within the rare disease space. \nEvent Agenda: \n6:00PM to 7:00PM – Sharon will discuss what Alexion Pharmaceuticals is doing in terms of research in the rare disease space. This will be followed by a short Q&A session with audience. \n7:00PM to 8:00PM – Networking session with light appetizers provided. \n* Registration does not guarantee your admittance into the event due to the high demand expected. We will personally notify those we are able to accommodate for the event. Either way\, please follow us for details on future events. \n** No walk-ins will be admitted. You must RSVP in order to attend. \nMore on the event organizers: \nAbout BioXchange \nBioXchange is a premier life sciences networking organization founded by some of the most networked people in the Boston life sciences hub. Our goal is to help connect companies and individuals within the epicenter of life sciences industry located in Massachusetts through monthly events. Events are typically held in the two largest concentrated areas for life sciences companies: Cambridge and Waltham. These events are setup to cater to all sectors of the industry from scientists\, law firms\, service companies\, staffing firms\, and many others. \nFeel free to reach out to us directly if you have any questions or concerns at bioxchange.boston@gmail.com. \nAbout Alexion Pharmaceuticals \nAlexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery\, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years\, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS)\, anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders\, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition\, the company is developing several mid-to-late-stage therapies\, including a second complement inhibitor\, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies\, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology\, nephrology\, neurology\, and metabolic disorders. Alexion has been named to the Forbes’ list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston\, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.
URL:https://scienceinboston.com/event/alexion-research-building-a-pipeline-to-service-patients-with-rare-disease/
LOCATION:Alexion Pharmaceuticals Inc.\, 121 Seaport Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191105T180000
DTEND;TZID=America/New_York:20191105T200000
DTSTAMP:20260715T030505
CREATED:20191021T134936Z
LAST-MODIFIED:20191021T134936Z
UID:27353-1572976800-1572984000@scienceinboston.com
SUMMARY:Alexion Research: Building a Pipeline to Service Patients with Rare Disease
DESCRIPTION:BioXchange and Alexion Pharmaceuticals Present: Sharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals\n\n\n\n\n\n\nAbout this Event\n\n\n\nThis event is one of two sessions: \nBoston\, MA – November 5th \nNew Haven\, CT – November 12th \nOverview: \nSharon Barr; VP\, Global Head of Research at Alexion Pharmaceuticals; will provide an overview of Alexion Pharmaceuticals and the overall company culture. Along with this\, she will go into a deep discussion with regards to the research the company is currently working on within the rare disease space. \nEvent Agenda: \n6:00PM to 7:00PM – Sharon will discuss what Alexion Pharmaceuticals is doing in terms of research in the rare disease space. This will be followed by a short Q&A session with audience. \n7:00PM to 8:00PM – Networking session with light appetizers provided. \n* Registration does not guarantee your admittance into the event due to the high demand expected. We will personally notify those we are able to accommodate for the event. Either way\, please follow us for details on future events. \n** No walk-ins will be admitted. You must RSVP in order to attend. \nMore on the event organizers: \nAbout BioXchange \nBioXchange is a premier life sciences networking organization founded by some of the most networked people in the Boston life sciences hub. Our goal is to help connect companies and individuals within the epicenter of life sciences industry located in Massachusetts through monthly events. Events are typically held in the two largest concentrated areas for life sciences companies: Cambridge and Waltham. These events are setup to cater to all sectors of the industry from scientists\, law firms\, service companies\, staffing firms\, and many others. \nFeel free to reach out to us directly if you have any questions or concerns at bioxchange.boston@gmail.com. \nAbout Alexion Pharmaceuticals \nAlexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery\, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years\, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS)\, anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders\, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition\, the company is developing several mid-to-late-stage therapies\, including a second complement inhibitor\, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies\, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology\, nephrology\, neurology\, and metabolic disorders. Alexion has been named to the Forbes’ list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston\, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.
URL:https://scienceinboston.com/event/alexion-research-building-a-pipeline-to-service-patients-with-rare-disease-2/
LOCATION:Alexion Pharmaceuticals Inc.\, 121 Seaport Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
END:VCALENDAR